- Home
- CNMD vs GERN Comparison
CNMD vs GERN Comparison
Compare CNMD & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNMD | GERN |
|---|---|---|
| Founded | 1970 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNMD | GERN |
|---|---|---|
| Price | $36.81 | $1.42 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $46.25 | $2.17 |
| AVG Volume (30 Days) | 386.2K | ★ 14.8M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $1,374,724,000.00 | N/A |
| Revenue This Year | $0.82 | $26.91 |
| Revenue Next Year | $5.48 | $43.75 |
| P/E Ratio | $25.18 | ★ N/A |
| Revenue Growth | ★ 5.18 | N/A |
| 52 Week Low | $33.21 | $1.04 |
| 52 Week High | $60.80 | $2.01 |
Technical Indicators
Market Signals| Indicator | CNMD | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 37.29 |
| Support Level | $35.37 | $1.24 |
| Resistance Level | $46.08 | $1.49 |
| Average True Range (ATR) | 1.88 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 30.98 | 1.45 |
Price Performance
Historical ComparisonAbout CNMD CONMED Corporation
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.